Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks

Leukemia Research, 05/25/2012

The results suggest that acute promyelocytic leukemia (APL) patients benefit from combination all–trans retinoic acid (ATRA)/arsenic trioxide (ATO)/chemotherapy, and that this regimen is especially beneficial for patients with high–risk prognostic factors.

Print Article Summary Cat 2 CME Report